Last reviewed · How we verify
NCT03494712
Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers
Completed
Phase 1
Last updated 17 February 2020
What this trial tests
Phase 1 trial testing S 95010 in Cardiovascular Diseases in 49 participants. Completed in 10 April 2019.
Timeline
21 February 2018
Primary endpoint
10 April 2019
10 April 2019
10 April 2019
Quick facts
| Lead sponsor | Institut de Recherches Internationales Servier |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 21 February 2018 |
| Primary completion | 10 April 2019 |
| Estimated completion | 10 April 2019 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- S 95010 — full drug profile →
- Placebo
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Institut de Recherches Internationales Servier — full company profile →
Who can join
Adults 18 to 45, male only, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to assess, the safety and tolerability of single ascending doses of S 95010 and to assess the pharmacokinetics (PK) of S 95010.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.
Huang CK, Kafert-Kasting S, Thum T. · · 2020 · cited 162× · PMID 32105576 · DOI 10.1161/circresaha.119.315856 -
Reexamining assumptions about miRNA-guided gene silencing.
Kilikevicius A, Meister G, Corey DR. · · 2022 · cited 153× · PMID 34967419 · DOI 10.1093/nar/gkab1256 -
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0 -
Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.
Nappi F. · · 2024 · cited 72× · PMID 38612441 · DOI 10.3390/ijms25073630 -
Small non-coding RNA therapeutics for cardiovascular disease.
Shah AM, Giacca M. · · 2022 · cited 60× · PMID 36106499 · DOI 10.1093/eurheartj/ehac463 -
Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases.
Singh DD, Singh DD, Kim Y, Choi SA, et al · · 2023 · cited 35× · PMID 37371099 · DOI 10.3390/cells12121629 -
Functional Role of microRNAs in Regulating Cardiomyocyte Death.
Kansakar U, Varzideh F, Mone P, Jankauskas SS, et al · · 2022 · cited 33× · PMID 35326433 · DOI 10.3390/cells11060983 -
Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis.
Singh D, Rai V, Agrawal DK. · · 2022 · cited 24× · PMID 36430208 · DOI 10.3390/ijms232213731
Verify or expand the search:
- PubMed search for NCT03494712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Institut de Recherches Internationales Servier trials
Trials by the same sponsor.
- NCT07227857 — A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopath · Phase 1, PHASE2 · recruiting
- NCT06501625 — Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta · Phase 1, PHASE2 · recruiting
- NCT06465953 — Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod · Phase 3 · recruiting
- NCT06225999 — Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not · Phase 2 · active not recruiting
- NCT05674474 — A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hep · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03494712 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Recherches Internationales Servier
- Last refreshed: 17 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing